Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical injectable BL-B01D1 (EGFR × HER3-ADC) independently developed by the company to treat advanced locally or metastatic nasopharyngeal cancer patients has been included in the list of breakthrough treatment types by the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as the “Drug Review Center”), which has recently been announced.